Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays

Clare McCormick-Baw, Rita Hollaway, Dominick Cavuoti

Research output: Contribution to journalArticle

Abstract

Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.

Original languageEnglish (US)
Pages (from-to)139-144
Number of pages6
JournalClinical Microbiology Newsletter
Volume40
Issue number17
DOIs
StatePublished - Sep 1 2018

Fingerprint

Interferon-gamma Release Tests
Latent Tuberculosis
Mycobacterium Infections
Mycobacterium tuberculosis
Tuberculin Test
Tuberculin
Infection
Skin Tests
History
Bacteria
Delivery of Health Care
Sensitivity and Specificity
Skin
Acids
Population

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays. / McCormick-Baw, Clare; Hollaway, Rita; Cavuoti, Dominick.

In: Clinical Microbiology Newsletter, Vol. 40, No. 17, 01.09.2018, p. 139-144.

Research output: Contribution to journalArticle

@article{e8aa7973d3be46869ab31014599d0440,
title = "Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays",
abstract = "Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.",
author = "Clare McCormick-Baw and Rita Hollaway and Dominick Cavuoti",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.clinmicnews.2018.08.005",
language = "English (US)",
volume = "40",
pages = "139--144",
journal = "Clinical Microbiology Newsletter",
issn = "0196-4399",
publisher = "Elsevier Inc.",
number = "17",

}

TY - JOUR

T1 - Diagnosis of Latent Mycobacterium tuberculosis Infection in the Era of Interferon Gamma Release Assays

AU - McCormick-Baw, Clare

AU - Hollaway, Rita

AU - Cavuoti, Dominick

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.

AB - Mycobacterium tuberculosis (MTB), an acid-fast bacterium, is a leading cause of respiratory illness and death worldwide. Individuals can be latently infected and can harbor the organism without clinical evidence of disease for years. Screening and treatment of numerous populations, including health care workers, recent contacts of actively infected individuals, immunocompromised individuals, children, and immigrants from countries where MTB is endemic, is essential to eradicate the infection by 2050, as the World Health Organization envisions. Detection of active and latent infection historically has utilized tuberculin skin tests and other clinical findings. Interferon gamma release assays can test whether a patient has had MTB exposure with improved sensitivity and specificity over tuberculin skin testing. This article reviews the history of MTB testing, compares available interferon gamma release assays, and discusses the new developments related to latent-MTB infection testing.

UR - http://www.scopus.com/inward/record.url?scp=85051643442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051643442&partnerID=8YFLogxK

U2 - 10.1016/j.clinmicnews.2018.08.005

DO - 10.1016/j.clinmicnews.2018.08.005

M3 - Article

AN - SCOPUS:85051643442

VL - 40

SP - 139

EP - 144

JO - Clinical Microbiology Newsletter

JF - Clinical Microbiology Newsletter

SN - 0196-4399

IS - 17

ER -